US Patent Grant

RNS Number:8013E
Genosis PLC
01 October 2007


FOR IMMEDIATE RELEASE                                             1 OCTOBER 2007



                                  GENOSIS PLC

                US PATENT OFFICE TO GRANT OVARIAN RESERVE PATENT

Genosis plc (AIM: GNOS), a UK company focusing on consumer products for
reproductive health, is pleased to announce that it has received notification of
allowance from the US Patent and Trademark Office for its patent application
covering urinary assays for Ovarian Reserve.  The patent will provide protection
till 2023.

Genosis' Fertell  products are protected by six patent families that have been
granted in both Europe and the US.  Fertell is sold in the UK through Alliance
Boots and in the US through CVS and Longs Drugs as well as on the internet,
www.fertell.com.

Commenting on the announcement, Paul Bateman, CEO of Genosis said:

"We are delighted that this US patent application for our Ovarian Reserve assay
has been deemed both novel and inventive.   This provides further strengthening
of Genosis' six patent families which offer broad protection for our unique male
and female fertility tests, Fertell - the world's only FDA cleared "at-home"
fertility test for couples."

                                    - ENDS -

For further details, please contact:

Genosis                                                Today on:
Paul Bateman, CEO / Jonathan Pockson, CFO              Tel: +44 (0) 1483774050

Buchanan Communications
Lisa Baderoon / Rebecca Skye Dietrich                  Tel: +44 (0) 20 7466 5000

Evolution Securities
Tim Worlledge / Bobbie Hilliam                         Tel: +44 (0) 20 7071 4300




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCBLGDCCUDGGRI

Genosis (LSE:GNOS)
過去株価チャート
から 5 2024 まで 6 2024